TY - JOUR
T1 - Dual action of angiotensin II on coronary resistance in the isolated perfused rabbit heart
AU - Pörsti, I
AU - Hecker, M
AU - Bassenge, E
AU - Busse, R
PY - 1993/12
Y1 - 1993/12
N2 - We studied the functional role of angiotensin II (AII) receptor subtypes and vasodilatory endothelial autacoid release in response to AII in isolated perfused rabbit hearts. AII infusion induced biphasic changes in coronary perfusion pressure (CPP): an initial increase was followed by a decrease until a plateau was reached. At higher concentrations of AII (> or = 10 nmol/l) this plateau phase was lower than the initial CPP level. AII infusion elicited inverse changes in peak left ventricular pressure (LVP): coronary constriction was associated with a transient decline, and during the plateau phase LVP was clearly increased. AII also moderately augmented prostacyclin (PGI2) release from the coronary vascular bed. The AII-induced changes in CPP, LVP, and PGI2 release were effectively inhibited by the AT1 receptor subtype antagonist ICI D8731 (30 nmol/l), but not by the AT2 receptor antagonist CGP 42112 (30 nmol/l). The adenosine A1 receptor antagonist 8-phenyltheophylline (0.1 mumol/l) attenuated the decline in CPP following the constriction phase without affecting the changes in LVP during AII infusion. The cyclooxygenase inhibitor diclofenac (1 mmol/l) had no effect on the AII-induced changes in CPP, whereas the nitric oxide-synthase inhibitor NG-nitro-L-arginine (30 mumol/l) markedly potentiated the vasoconstriction but was without effect on the plateau phase of the response. In contrast to AII, the thromboxane analogue U46619 elicited sustained increases in CPP which were associated with slight decreases in LVP.(ABSTRACT TRUNCATED AT 250 WORDS)
AB - We studied the functional role of angiotensin II (AII) receptor subtypes and vasodilatory endothelial autacoid release in response to AII in isolated perfused rabbit hearts. AII infusion induced biphasic changes in coronary perfusion pressure (CPP): an initial increase was followed by a decrease until a plateau was reached. At higher concentrations of AII (> or = 10 nmol/l) this plateau phase was lower than the initial CPP level. AII infusion elicited inverse changes in peak left ventricular pressure (LVP): coronary constriction was associated with a transient decline, and during the plateau phase LVP was clearly increased. AII also moderately augmented prostacyclin (PGI2) release from the coronary vascular bed. The AII-induced changes in CPP, LVP, and PGI2 release were effectively inhibited by the AT1 receptor subtype antagonist ICI D8731 (30 nmol/l), but not by the AT2 receptor antagonist CGP 42112 (30 nmol/l). The adenosine A1 receptor antagonist 8-phenyltheophylline (0.1 mumol/l) attenuated the decline in CPP following the constriction phase without affecting the changes in LVP during AII infusion. The cyclooxygenase inhibitor diclofenac (1 mmol/l) had no effect on the AII-induced changes in CPP, whereas the nitric oxide-synthase inhibitor NG-nitro-L-arginine (30 mumol/l) markedly potentiated the vasoconstriction but was without effect on the plateau phase of the response. In contrast to AII, the thromboxane analogue U46619 elicited sustained increases in CPP which were associated with slight decreases in LVP.(ABSTRACT TRUNCATED AT 250 WORDS)
KW - 6-Ketoprostaglandin F1 alpha/pharmacology
KW - Adenosine/antagonists & inhibitors
KW - Amino Acid Oxidoreductases/antagonists & inhibitors
KW - Angiotensin I/metabolism
KW - Angiotensin II/antagonists & inhibitors
KW - Angiotensin Receptor Antagonists
KW - Animals
KW - Biphenyl Compounds/pharmacology
KW - Blood Pressure/drug effects
KW - Coronary Circulation/drug effects
KW - Coronary Vessels/drug effects
KW - Cyclooxygenase Inhibitors/pharmacology
KW - Endothelium, Vascular/drug effects
KW - Heart/drug effects
KW - In Vitro Techniques
KW - Male
KW - Muscle, Smooth, Vascular/drug effects
KW - Myocardial Contraction/drug effects
KW - Nitric Oxide Synthase
KW - Oligopeptides/pharmacology
KW - Organ Size/drug effects
KW - Quinolines/pharmacology
KW - Rabbits
KW - Receptors, Angiotensin/drug effects
KW - Vascular Resistance/drug effects
KW - Vasodilation/drug effects
U2 - 10.1007/BF00167243
DO - 10.1007/BF00167243
M3 - Article
C2 - 7510856
VL - 348
SP - 650
EP - 658
IS - 6
ER -